Online inquiry

IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1956MR)

This product GTTS-WQ1956MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SLITRK6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_032229.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84189
UniProt ID Q9H5Y7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1956MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9566MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ13124MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ3648MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ5325MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ10302MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ12104MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ7161MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FG-3019
GTTS-WQ11315MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-524
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW